SillaJen Company Description

SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea.

Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine.

SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

SillaJen, Inc.

Country	South Korea
Founded	2006
Industry	Biological Products, Except Diagnostic Substances
Employees	37
CEO	Jaekyung Kim

Contact Details

Address: 109, Sogong-ro Seoul, 04525 South Korea
Phone	82 2 368 2600
Website	sillajen.com

Stock Details

Ticker Symbol	215600
Exchange	Korea Exchange - KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Jaekyung Kim	Chief Executive Officer
Suk Song Myung	Chief Financial Officer